
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical is expected to show significant growth over the coming years, thanks to its robust commercial progress and pipeline growth, with over 30 active projects and four commercial manufacturing site transfer programs since October 2025. The company has a strong leadership team led by CEO Paul Josephs, who has brought a new level of focus and energy to Lifecore and is driving capacity utilization through de-risked commercial opportunities such as site transfers. With a solid balance sheet and expected annual free cash flow of over $10 million in 2026, Lifecore is well positioned for future success.
Bears say
Lifecore Biomedical is currently in the crucial "execution" phase of its turnaround effort under the leadership of CEO Paul Josephs, with emphasis on new business wins and expense management. While new business wins and expense reduction have shown significant progress, the recent hire of Amber Shook as Chief of Staff/Head of Business Transformation suggests that the company still has room for improvement in terms of becoming more streamlined and efficient. Additionally, Lifecore's recent news flow has shown potential for growth, but it may still face challenges in optimizing its business processes and procurement practices.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares